Bitcoin News Today: U.S.-China Trade Clarity Fuels $2.8B Bitcoin Push by Jiuzi, Solventum

Jiuzi Holdings, a prominent player in the cryptocurrency and blockchain sector, has announced a strategic partnership with Solventum Corp. (SOLV) to launch a $2.8 billion initiative focused on Bitcoin infrastructure development and cross-border digital asset solutions. The collaboration aims to leverage Solventum's expertise in healthcare and data science, alongside Jiuzi's blockchain capabilities, to create scalable financial tools for institutional investors and enterprises. The move comes amid growing regulatory clarity in global crypto markets, including recent U.S.-China trade agreements that have spurred stablecoin activity and cross-border digital asset adoption, according to a OneSafe analysis.

The partnership follows Solventum's recent leadership changes, including the appointment of Heather Knight as Chief Commercial Officer, who previously served as COO at Baxter International, according to a Barchart report. Knight's transition to Solventum underscores the company's pivot toward expanding its digital asset division, which now accounts for a significant portion of its $12.5 billion market capitalization. However, Solventum's stock has faced headwinds, with shares falling 1.15% on October 24, 2025, marking a 16.85% decline from its 52-week high, a trend noted in the OneSafe analysis. Analysts attribute the underperformance to broader market volatility and uncertainty around the company's upcoming quarterly earnings report, where it is projected to report adjusted earnings per share (EPS) of $1.42, a 23.5% year-over-year increase.

The initiative with Jiuzi also aligns with recent developments in the Solana blockchain ecosystem, where China Asset Management recently launched the first spot Solana ETF on the Hong Kong Stock Exchange, according to an ETF Express report. This trend highlights increasing institutional interest in blockchain-based financial products, a sector where Jiuzi and Solventum aim to strengthen their foothold. The U.S.-China trade agreement, which included provisions for harmonizing digital currency regulations, has further bolstered confidence in cross-border crypto projects, with stablecoin transactions surging post-announcement.

Solventum's stock faces mixed analyst sentiment, with a "Moderate Buy" rating from 15 covering analysts and an average price target of $85.60, implying an 18.4% upside from current levels. However, the company's healthcare segment, which includes medical device components and purification technologies, continues to face margin pressures, contributing to its recent underperformance relative to the S&P 500, as the OneSafe analysis observed.